Navigation Links
Study suggests drug significantly improves glycemic control in type 1 diabetics on insulin
Date:6/15/2011

BUFFALO, N.Y. -- Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide, an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control of their blood glucose levels.

If the findings are confirmed in a larger, prospective, randomized study now being planned by the UB researchers, they could mean the first significant, new treatment for type 1 diabetes since insulin was discovered and made available in the 1920s.

The research has been published online ahead of print at http://www.eje-online.org/content/early/2011/06/06/EJE-11-0330.abstract ('doi: 10.1530/EJE-11-0330') in the European Journal of Endocrinology. It also was recently presented at the annual meeting of the Endocrine Society in Boston, where it received recognition as one of the most outstanding abstracts presented and the best in the field of diabetes.

"Since the development of injectable insulin, there has been nothing definitive in terms of a significant advance in type 1 diabetes treatments," says Paresh Dandona, MD, PhD, UB distinguished professor of medicine in the School of Medicine and Biomedical Sciences and senior author on the study. "That is the tragedy of the type 1 diabetic.

"This study shows that liraglutide can provide even well-controlled type 1 diabetics with additional benefits that help them achieve even better blood glucose levels," says Dandona.

The patients on liraglutide, which is marketed as Victoza, also saw a reduction in appetite and food intake and the paper reports that body weight significantly fell in patients who took the drug for 24 weeks.

The unfunded study was a retrospective analysis of data. It was conducted at Kaleida Health's Diabetes-Endocrinology Center of Western New York, which Dandona directs.

At the start of the study, all 14 patients had hemoglobin A1C levels of under 7, which is considered optimal. They were characterized in the paper as "well-controlledmeticulous and disciplined" in terms of their ability to control their blood glucose levels with insulin.

Nevertheless, Dandona notes, even well-controlled type 1 diabetics still experience "glycemic excursions," fairly wide swings in their blood glucose numbers ranging from the hyperglycemic, from 150 milligrams per deciliter to 250 mg/dl or higher to the hypoglycemic, under 70 mg/dl.

"The addition of liraglutide to insulin therapy in these well-controlled type 1 diabetics resulted in a significant and rapid reduction in glycemic excursions and, as a consequence, a rapid reduction in the amount of insulin they needed to take," Dandona explains.

Several figures in this presentation by Dandona clearly demonstrate this effect.

These improvements occurred rapidly, within 1-2 days of beginning treatment with liraglutide and they reversed just as rapidly when treatment was discontinued, signifying that it was the drug that was responsible for these beneficial effects.

The mechanism behind these improvements is not well-understood but Dandona and his co-authors suggest that liraglutide may be suppressing the post-meal increase in glucagon, the hormone that raises glucose levels, in type 1 diabetics.

Dandona and his colleagues are now planning a much larger, multicenter study of liraglutide in type 1 diabetics.

"We will be investigating in detail the hypothesis that it is liraglutide's ability to suppress glucagon that significantly reduces the wide swings in blood glucose levels that type 1 diabetics -- even those with very good glucose control -- live with everyday," says Dandona.

The retrospective study involved 14 adult type 1 diabetics who took liraglutide for periods ranging from one week to 24 weeks.


'/>"/>

Contact: Ellen Goldbaum
goldbaum@buffalo.edu
716-645-4605
University at Buffalo
Source:Eurekalert

Related medicine news :

1. Sudden cardiac death subject of sweeping UCSF study in San Francisco
2. UF study: When singing mice choose a mate, a skillful song gets the gal
3. COPD Drug Via Mist Inhaler Could Raise Death Risk: Study
4. JAMA study points to patient safety risks outside hospital walls
5. Study Finds Equal Number of Errors in Hospitals, Doctors Offices
6. Sleeptime Head-Cooling Cap Eases Insomnia, Study Finds
7. Ancestry plays vital role in nutrition and disease, study shows
8. Life Often Shorter for the Homeless: Study
9. College Students Who Sleep in Drink More, Study Less
10. Nanotubes could pose health risk to production line staff, study suggests
11. Spending on Glaucoma Meds Rising in U.S., Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ... and night. No other wearable health technology on the market can deliver all that ... poeple more meaningful insights about their health than the usual heart rate and steps ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... pharmaceutical organizations to build intelligent, connected applications, was named the best Sales Team ... , The winner announcement was made today by the Software & Information Industry ...
(Date:11/30/2016)... ... 30, 2016 , ... "I hate when the mixture of saliva and toothpaste ... an inventor from Bridgewater, N.J. "I thought that there had to be a way ... developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... tech functions and stylish design wanted by today’s consumers at an affordable price, ... Darin Philip says the new watch is “a game changer” when it comes ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 On ... down 1.36%; the Dow Jones Industrial Average edged 0.36% higher, ... 2,191.08, down 0.35%. Losses were broad based as six out ... has initiated research reports on the following Services equities: Myriad ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
(Date:12/2/2016)... The concept of rare diseases and the idea that a ... been taking shape in Europe since ... related to orphan medicinal products have been emerging at both ... individually. Many member states in the EU have led the ... products, the result of which took the shape of the ...
(Date:12/2/2016)... 1, 2016 Around the corners of world, ... each habitable land present over earth. Cancer has become ... in a life time this is because of the ... now. Given the steady increase in global cancer incidence ... spiraling healthcare costs of treatment, there is increasing interest ...
Breaking Medicine Technology: